Novo Nordisk | NVO - Equity Capital And Reserves


Novo Nordisk reported DKK33.81B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
Bausch Health Companies USD -802M 1.26B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 697.59M 60.58M Mar/2026
Corcept Therapeutics USD 705.78M 67.79M Jun/2026
Drreddys Laboratories INR 380.46B 376.31B Mar/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Novo Nordisk DKK 33.81B 169.25B Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Perrigo USD 2.52B 17M Jun/2026
Phibro Animal Health USD 385.48M 23.65M Jun/2026
Prestige Brands USD 1.92B 29.2M Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Zoetis USD 3.15B 85M Jun/2026